Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Deferred Taxes: 2014-2024

Historic Deferred Taxes for Ani Pharmaceuticals (ANIP) over the last 11 years, with Dec 2024 value amounting to -$21.9 million.

  • Ani Pharmaceuticals' Deferred Taxes rose 436.44% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year increase of 55.62%. This contributed to the annual value of -$21.9 million for FY2024, which is 86.65% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Deferred Taxes of -$21.9 million as of FY2024, which was down 86.65% from -$11.7 million recorded in FY2023.
  • Ani Pharmaceuticals' Deferred Taxes' 5-year high stood at -$11.7 million during FY2023, with a 5-year trough of -$21.9 million in FY2024.
  • Over the past 3 years, Ani Pharmaceuticals' median Deferred Taxes value was -$15.3 million (recorded in 2022), while the average stood at -$16.3 million.
  • Its Deferred Taxes has fluctuated over the past 5 years, first rose by 23.03% in 2023, then tumbled by 86.65% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Deferred Taxes (Yearly) stood at -$13.2 million in 2020, then declined by 26.88% to -$16.8 million in 2021, then grew by 8.96% to -$15.3 million in 2022, then grew by 23.03% to -$11.7 million in 2023, then crashed by 86.65% to -$21.9 million in 2024.